JMP maintains Dynavax at market outperform

Dynavax Technologies Corp. was reiterated at market outperform with a $9 price target by JMP Securities analyst Charles C. Duncan after third-quarter results were in line with JMP and consensus estimates for a $0.4 million top line and beat JMP and consensus estimate bottom-line forecasts with a $0.33 loss per share versus $0.39 loss per share. The company made progress with its ragweed allergy compound Tolamba and its hepatitis-B virus agent Heplisav. Shares of the Berkeley, Calif.-based biopharmaceutical company were down $0.24, or 3.89%, at $5.93 on volume of 14,404 shares versus the three-month running average of 44,590.8 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.